Myelodysplastic/myeloproliferative Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MYL075 MIFTS: 52	Myelodysplastic/myeloproliferative Neoplasm Categories: Blood diseases, Cancer diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Myelodysplastic/myeloproliferative Neoplasm

MalaCards integrated aliases for Myelodysplastic/myeloproliferative Neoplasm:

Name: Myelodysplastic/myeloproliferative Neoplasm ¹¹ ¹⁹ ¹⁴ ³⁶ ¹⁶

Myelodysplastic-Myeloproliferative Diseases ⁴³ ⁷¹ ⁷⁵

Myelodysplastic/myeloproliferative Disease ¹⁹ ⁵⁸

Myeloproliferative/myelodysplastic Syndromes ¹¹

Myelodysplastic Myeloproliferative Disease ¹¹

Myelodysplastic Myeloproliferative Cancer ¹¹

Characteristics:

Prevelance:

Myelodysplastic/myeloproliferative Disease: 1-9/1000000 (Europe) ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other leukaemias of specified cell type

Myelodysplastic and myeloproliferative disease, not elsewhere classified

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Myelodysplastic and myeloproliferative neoplasms

Myelodysplastic and myeloproliferative neoplasms, unspecified

Other specified myelodysplastic and myeloproliferative neoplasms

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:4972

MeSH ⁴³ D054437

NCIt ⁴⁹ C27262

SNOMED-CT ⁶⁸ 445738007

ICD10 ³¹ C94.6

MESH via Orphanet ⁴⁴ D054437

UMLS via Orphanet ⁷² C1301355

Orphanet ⁵⁸ ORPHA98275

EFO ¹⁶ EFO_1000388

ICD11 ³³ 110923694 110923694/other 110923694/unspecified

UMLS ⁷¹ C1301355

Sources

Summaries for Myelodysplastic/myeloproliferative Neoplasm

GARD: ¹⁹ Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells. These disease have features of both myelodysplastic syndromes and myeloproliferative disorders. In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells, white blood cells, or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of Myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a Myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak.

MalaCards based summary: Myelodysplastic/myeloproliferative Neoplasm, also known as myelodysplastic-myeloproliferative diseases, is related to thrombocytosis and atypical chronic myeloid leukemia, bcr-abl1 negative. An important gene associated with Myelodysplastic/myeloproliferative Neoplasm is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Mercaptopurine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and bone, and related phenotypes are Decreased viability and Decreased substrate adherent cell growth

Disease Ontology: ¹¹ A myeloid neoplasm that results in the overproduction of white blood cells.

Wikipedia: ⁷⁵ Myelodysplastic-myeloproliferative diseases are a category of hematological malignancies which have... more...

Sources

Related Diseases for Myelodysplastic/myeloproliferative Neoplasm

Diseases related to Myelodysplastic/myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)

#	Related Disease	Score	Top Affiliating Genes
1	thrombocytosis	31.0	U2AF1 TET2 JAK2 CSF2 ASXL1
2	atypical chronic myeloid leukemia, bcr-abl1 negative	30.9	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PDGFRB
3	refractory anemia	30.7	TET2 ASXL1
4	cardiofaciocutaneous syndrome 1	30.4	PTPN11 NRAS NF1 HRAS
5	myeloid sarcoma	30.3	U2AF1 KIT FLT3
6	systemic mastocytosis with associated hematologic neoplasm	30.3	TET2 SRSF2 KIT ASXL1
7	li-fraumeni syndrome	30.3	U2AF1 NF1 LUC7L2 HRAS ETV6
8	acute erythroid leukemia	30.2	U2AF1 KIT JAK2 FLT3
9	juvenile myelomonocytic leukemia	30.1	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
10	aplastic anemia	30.0	U2AF1 LUC7L2 FLT3 CSF3R CSF2 ASXL1
11	hypereosinophilic syndrome	30.0	PDGFRB KIT JAK2 CSF2 ABL1
12	acute megakaryocytic leukemia	30.0	U2AF1 KIT JAK2 FLT3 CSF2
13	chronic myelomonocytic leukemia	30.0	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
14	mastocytosis	29.8	TET2 SRSF2 PDGFRB KIT JAK2 FLT3
15	systemic mastocytosis	29.8	U2AF1 TET2 SRSF2 PTPN11 PDGFRB KIT
16	thrombocytopenia	29.7	U2AF1 PTPN11 KIT JAK2 FLT3 ETV6
17	myeloproliferative neoplasm	29.5	U2AF1L4 U2AF1 TET2 SRSF2 PTPN11 PDGFRB
18	deficiency anemia	29.5	U2AF1 NRAS LUC7L2 KIT JAK2 FLT3
19	hematologic cancer	29.4	U2AF1 PTPN11 PDGFRB LUC7L2 KIT JAK2
20	leukemia, acute lymphoblastic	29.4	U2AF1 PTPN11 KIT JAK2 HRAS FLT3
21	myeloid leukemia	29.3	U2AF1 TET2 SETBP1 PTPN11 PDGFRB NRAS
22	myelofibrosis	29.3	U2AF1 TET2 SRSF2 SETBP1 PDGFRB KIT
23	acute promyelocytic leukemia	29.2	U2AF1 TET2 NRAS KIT HRAS FLT3
24	essential thrombocythemia	29.0	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 LUC7L2
25	leukemia	29.0	U2AF1 PTPN11 PDGFRB NRAS NF1 KIT
26	myelodysplastic syndrome	28.8	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
27	leukemia, acute myeloid	28.7	U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
28	leukemia, chronic myeloid	28.6	U2AF1 TET2 SETBP1 PTPN11 PDGFRB NRAS
29	aml with myelodysplasia-related features	11.4
30	unclassified myelodysplastic/myeloproliferative disease	11.4
31	acute myeloid leukemia with recurrent genetic anomaly	10.4
32	keratosis pilaris atrophicans faciei	10.4	PTPN11 NF1
33	childhood leptomeningeal melanoma	10.4	NRAS HRAS
34	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	10.4	JAK2 ABL1
35	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	10.3	FLT3 ABL1
36	lymphoblastic leukemia, acute, with lymphomatous features	10.3	JAK2 ABL1
37	melanocytic nevus syndrome, congenital	10.3	NRAS HRAS
38	wernicke encephalopathy	10.3	U2AF1 JAK2 ASXL1
39	intellectual developmental disorder, autosomal dominant 29	10.3	SETBP1 ABL1
40	vexas syndrome	10.3	U2AF1 TET2 ASXL1
41	chronic myelogenous leukemia, bcr-abl1 positive	10.3	NRAS CSF3R ABL1
42	stress polycythemia	10.3	JAK2 CSF3R ABL1
43	acute megakaryoblastic leukemia in down syndrome	10.3	SRSF2 PTPN11 NRAS
44	testicular spermatocytic seminoma	10.3	PTPN11 HRAS
45	meningeal melanomatosis	10.3	NRAS HRAS
46	pulmonic stenosis	10.3	PTPN11 NF1 HRAS
47	skin granular cell tumor	10.3	PTPN11 NF1
48	multiple enchondromatosis, maffucci type	10.3	TET2 PTPN11 NF1
49	noonan syndrome-like disorder with loose anagen hair 1	10.3	PTPN11 HRAS
50	primary hypereosinophilic syndrome	10.3	PDGFRB ETV6

Graphical network of the top 20 diseases related to Myelodysplastic/myeloproliferative Neoplasm:

Sources

Symptoms & Phenotypes for Myelodysplastic/myeloproliferative Neoplasm

GenomeRNAi Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

²⁵ (show all 19)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.84	HRAS
2	Decreased viability	GR00055-A-2	10.84	HRAS
3	Decreased viability	GR00173-A	10.84	FLT3
4	Decreased viability	GR00221-A-1	10.84	ABL1 ETNK1 HRAS NF1 NRAS PDGFRB
5	Decreased viability	GR00221-A-2	10.84	ABL1 ETNK1 HRAS JAK2 NF1
6	Decreased viability	GR00221-A-3	10.84	ABL1 ETNK1 HRAS NRAS PDGFRB
7	Decreased viability	GR00221-A-4	10.84	ETNK1 NF1 PDGFRB FLT3
8	Decreased viability	GR00249-S	10.84	NF1
9	Decreased viability	GR00301-A	10.84	KIT
10	Decreased viability	GR00342-S-1	10.84	ABL1 ETNK1 PDGFRB
11	Decreased viability	GR00342-S-2	10.84	ABL1
12	Decreased viability	GR00342-S-3	10.84	ABL1
13	Decreased viability	GR00386-A-1	10.84	NF1
14	no effect	GR00402-S-1	10.19	ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
15	no effect	GR00402-S-2	10.19	ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
16	Decreased substrate adherent cell growth	GR00193-A-1	9.63	KIT
17	Decreased substrate adherent cell growth	GR00193-A-2	9.63	ABL1 KIT
18	Decreased substrate adherent cell growth	GR00193-A-4	9.63	ABL1 FLT3 KIT
19	Increased cell viability after pRB stimulation	GR00230-A-1	9.13	ABL1 ETNK1 KIT

MGI Mouse Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.39	ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
2	homeostasis/metabolism	MP:0005376	10.38	ABL1 ASXL1 CSF2 ETV6 FLT3 HRAS
3	growth/size/body region	MP:0005378	10.37	ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
4	neoplasm	MP:0002006	10.35	ASXL1 CSF2 ETV6 FLT3 HRAS JAK2
5	cellular	MP:0005384	10.28	ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
6	normal	MP:0002873	10.27	ABL1 ETV6 HRAS JAK2 KIT NF1
7	cardiovascular system	MP:0005385	10.25	ABL1 CSF2 CSF3R ETV6 HRAS JAK2
8	immune system	MP:0005387	10.22	ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
9	liver/biliary system	MP:0005370	10.2	ABL1 ASXL1 ETV6 JAK2 KIT NF1
10	behavior/neurological	MP:0005386	10.18	ABL1 ASXL1 CSF2 HRAS JAK2 KIT
11	no phenotypic analysis	MP:0003012	10.16	ETV6 FLT3 HRAS KIT NRAS PTPN11
12	embryo	MP:0005380	10.15	ABL1 CSF2 ETV6 JAK2 KIT NF1
13	digestive/alimentary	MP:0005381	10.13	ABL1 ASXL1 ETV6 HRAS KIT NF1
14	craniofacial	MP:0005382	10.11	ABL1 ASXL1 CSF2 HRAS KIT NF1
15	hematopoietic system	MP:0005397	10.09	ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
16	skeleton	MP:0005390	10.07	ABL1 ASXL1 CSF2 ETNK1 ETV6 FLT3
17	mortality/aging	MP:0010768	9.91	ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
18	integument	MP:0010771	9.32	CSF2 ETV6 HRAS JAK2 KIT NF1

Sources

Drugs & Therapeutics for Myelodysplastic/myeloproliferative Neoplasm

Drugs for Myelodysplastic/myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Mercaptopurine

Approved

Phase 3

50-44-2

667490

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Daunorubicin

Approved

Phase 3

20830-81-3

30323

Hydroxyurea

Approved

Phase 3

127-07-1

3657

Cytarabine

Approved, Investigational

Phase 3

147-94-4

6253

Idarubicin

Approved

Phase 3

58957-92-9

42890

Etoposide

Approved

Phase 3

33419-42-0

36462

Thiotepa

Approved, Investigational

Phase 2, Phase 3

52-24-4

5453

Amitriptyline

Approved

Phase 3

50-48-6

2160

Baclofen

Approved

Phase 3

1134-47-0

2284

Ketamine

Approved, Vet_approved

Phase 3

6740-88-1, 1867-66-9

3821

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Tioguanine

Approved

Phase 3

154-42-7

2723601

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

Estradiol

Approved, Investigational, Vet_approved

Phase 3

50-28-2

5757

Ethinylestradiol

Approved

Phase 3

57-63-6

5991

Polyestradiol phosphate

Approved

Phase 3

28014-46-2

Norgestimate

Approved, Investigational

Phase 3

35189-28-7

6540478

Moxifloxacin

Approved, Investigational

Phase 3

186826-86-8, 354812-41-2, 151096-09-2

152946

Isotretinoin

Approved, Investigational, Nutraceutical

Phase 3

302-79-4, 4759-48-2

5538 444795 5282379

Keratolytic Agents

Phase 3

Analgesics, Non-Narcotic

Phase 3

Dermatologic Agents

Phase 3

Antiviral Agents

Phase 3

Neurotransmitter Agents

Phase 3

Psychotropic Drugs

Phase 3

Antidepressive Agents

Phase 3

Etoposide phosphate

Phase 3

16760419

Adrenergic Agents

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Antidepressive Agents, Tricyclic

Phase 3

Anesthetics, Dissociative

Phase 3

GABA Agonists

Phase 3

Ophthalmic Solutions

Phase 3

Hydrocortisone-17-butyrate

Phase 3

Hydrocortisone 17-butyrate 21-propionate

Phase 3

Contraceptives, Oral

Phase 3

Contraceptive Agents

Phase 3

Estradiol 3-benzoate

Phase 3

Estradiol 17 beta-cypionate

Phase 3

Contraceptives, Oral, Combined

Phase 3

Norgestimate, ethinyl estradiol drug combination

Phase 3

Ginseng

Investigational, Nutraceutical

Phase 3

50647-08-0

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Bevacizumab

Approved, Investigational

Phase 1, Phase 2

216974-75-3

135329020

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Interventional clinical trials:

(show top 50) (show all 230)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study	Unknown status	NCT00043134	Phase 3	decitabine
2	Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood	Unknown status	NCT00047268	Phase 3	cytarabine;mercaptopurine
3	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
4	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
5	A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Completed	NCT00322101	Phase 3	cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
6	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation	Completed	NCT01305200	Phase 3	supersaturated calcium phosphate rinse
7	A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)	Completed	NCT00075816	Phase 3
8	Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia	Completed	NCT00003816	Phase 2, Phase 3	busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
9	Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation	Completed	NCT00265837	Phase 3
10	Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain.	Completed	NCT00666211	Phase 3
11	Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT)	Completed	NCT00750009	Phase 3
12	The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study	Completed	NCT00719563	Phase 3	American ginseng
13	The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study	Completed	NCT00516503	Phase 3	baclofen/amitriptyline/ketamine gel
14	Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation	Completed	NCT00755040	Phase 3	cyclosporine ophthalmic emulsion
15	HSCT-CHESS to Enhance Hematopoietic Transplant Recovery	Completed	NCT00782145	Phase 3
16	Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML	Completed	NCT00005863	Phase 3	cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
17	Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study	Completed	NCT00003593	Phase 3	asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
18	A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over	Completed	NCT00005823	Phase 3	cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19	Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation	Terminated	NCT00324324	Phase 3	moxifloxacin hydrochloride;Placebo
20	A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients	Unknown status	NCT00036712	Phase 2
21	Transplantation Using Umbilical Cord And Placental Blood	Unknown status	NCT00008164	Phase 2
22	A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies	Completed	NCT00462605	Phase 2	entinostat;sargramostim
23	A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome	Completed	NCT02666950	Phase 2	Cytarabine;WEE1 Inhibitor AZD1775
24	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
25	Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant	Completed	NCT00530218	Phase 2	Ganciclovir
26	Phase I/II Study of Ruxolitinib Plus Decitabine in Patients With Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia (AML)	Completed	NCT02257138	Phase 1, Phase 2	Decitabine;Ruxolitinib Phosphate
27	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
28	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
29	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
30	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial	Completed	NCT00105001	Phase 2	Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
31	Decidual Stromal Cells (DSC) in Treatment of Steroid-Refractory Graft-vs-host Disease in a Recipient of Matched Related Donor Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm	Completed	NCT04926194	Phase 2
32	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
33	Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies	Completed	NCT01056614	Phase 2	fludarabine phosphate;busulfan;tacrolimus;methotrexate
34	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
35	Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial	Completed	NCT00096161	Phase 2	Cyclosporine;Mycophenolate Mofetil;Pentostatin
36	Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation	Completed	NCT01527045	Phase 2	Atorvastatin Calcium;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
37	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
38	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies	Completed	NCT01384513	Phase 2	Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
39	A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation	Completed	NCT01789255	Phase 2	vorinostat;tacrolimus;cyclosporine;methotrexate
40	A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia	Completed	NCT01712308	Phase 2
41	Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders	Completed	NCT02210858	Phase 1, Phase 2	Tipifarnib
42	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
43	Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors	Completed	NCT00787761	Phase 2	busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
44	A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML	Completed	NCT00425477	Phase 2	bexarotene
45	A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease	Completed	NCT00410657	Phase 2	methylprednisolone;prednisone
46	Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study	Completed	NCT00093366	Phase 1, Phase 2	arsenic trioxide
47	A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease	Completed	NCT00096096	Phase 2	mycophenolate mofetil;tacrolimus
48	A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors	Completed	NCT00089037	Phase 1, Phase 2	methotrexate;sirolimus;tacrolimus
49	The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia	Completed	NCT00066248	Phase 2	cyproheptadine hydrochloride;megestrol acetate
50	Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation	Completed	NCT00055653	Phase 2	busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone

Search NIH Clinical Center for Myelodysplastic/myeloproliferative Neoplasm

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

imatinib

Imatinib mesylate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Myelodysplastic/myeloproliferative Neoplasm cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Myelodysplastic/myeloproliferative Neoplasm:

NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases

Embryonic/Adult Cultured Cells Related to Myelodysplastic/myeloproliferative Neoplasm:

Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Sources

Genetic Tests for Myelodysplastic/myeloproliferative Neoplasm

Sources

Anatomical Context for Myelodysplastic/myeloproliferative Neoplasm

Organs/tissues related to Myelodysplastic/myeloproliferative Neoplasm:

MalaCards : Bone Marrow, Myeloid, Bone, T Cells, Liver, Breast, Endothelial

Sources

Publications for Myelodysplastic/myeloproliferative Neoplasm

Articles related to Myelodysplastic/myeloproliferative Neoplasm:

(show top 50) (show all 156)

#	Title	Authors	PMID	Year
1	Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features. ⁶²	Su Z...Zhang J	36069745	2022
2	Challenges in the interpretation of a germline TERT variant in a patient with juvenile myelomonocytic leukemia. ⁶²	Janczar S...Mlynarski W	35927969	2022
3	Identification of cystic fibrosis transmembrane conductance regulator as a prognostic marker for juvenile myelomonocytic leukemia via the whole-genome bisulfite sequencing of monozygotic twins and data mining. ⁶²	Yi TT...Wu XD	36247890	2022
4	Low-level somatic JAK2 V617F mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR. ⁶²	Ji YS...Jang MA	35920094	2022
5	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. ⁶²	Karantanos T...Jain T	35379077	2022
6	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. ⁶²	Enjeti AK...Ross DM	35461716	2022
7	Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet's disease: Case report and the review of literature. ⁶²	Onaka T...Yonezawa A	35365826	2022
8	Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. ⁶²	Lee MY...Cho YU	35443589	2022
9	The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. ⁶²	O'Hagan Henderson S...Hilgendorf I	34471943	2022
10	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. ⁶²	Kanagal-Shamanna R...Bueso-Ramos C	34775472	2022
11	Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia. ⁶²	Finana C...Belver L	35267643	2022
12	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. ⁶²	Miltiadous O...Shukla N	34551074	2022
13	Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2/SF3B1 without anemia. ⁶²	Neumann NM...Wen KW	35050328	2022
14	CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis. ⁶²	Zhang X...Brody JP	35795468	2022
15	The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. ⁶²	Ibrar W...Yuan J	34270867	2021
16	Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. ⁶²	Kitazawa H...Takahashi Y	34580726	2021
17	Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. ⁶²	Kim HS...Kim M	34590720	2021
18	Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis. ⁶²	Kerneves P...Paubelle E	33586865	2021
19	Cerebral localization of chronic myelomonocytic leukemia: a case report. ⁶²	Hameon C...Gyan E	34303369	2021
20	Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. ⁶²	Hunter A...Padron E	33660195	2021
21	A case of successful acyclovir desensitization in a bone marrow transplant patient. ⁶²	Andrade DC...Rubio-Gomez H	32955996	2021
22	Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review. ⁶²	Zhao M...Gao S	34057843	2021
23	JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. ⁶²	Yasuda H...Komatsu N	33373831	2021
24	Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management. ⁶²	Gupta AK...Seth R	33796386	2021
25	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches. ⁶²	Diamantopoulos PT...Viniou NA	34868917	2021
26	Solving the Puzzle: The Diagnosis of Atypical Chronic Myeloid Leukemia, BCR-ABL1-Negative (aCML). ⁶²	Danyal K...Gardner JA	34491231	2021
27	Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations. ⁶²	Nm H...A O	34123720	2021
28	Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review. ⁶²	Barozzi E...Cattaneo D	35096623	2021
29	Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. ⁶²	Kuendgen A...Germing U	34869027	2021
30	MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene. ⁶²	Molony P...Sakhdari A	35038703	2021
31	NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? ⁶²	Forghieri F...Luppi M	33255988	2020
32	[Spontaneous remission of cutaneous myeloid sarcoma]. ⁶²	Allard T...Pedailles S	32854968	2020
33	Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. ⁶²	Jiang G...Chang H	32798550	2020
34	Update on CML-Like Disorders. ⁶²	Cross NCP	32862848	2020
35	RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. ⁶²	Hamdy N...Hammad M	32209330	2020
36	Successful prevention of severe allergic transfusion reactions with omalizumab. ⁶²	Shi S...Wang Y	32134497	2020
37	Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. ⁶²	Lasho T...Patnaik MM	32460983	2020
38	Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. ⁶²	Caye A...Bonnet D	31776464	2020
39	Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? ⁶²	Sangiorgio VFI...Arber DA	32460987	2020
40	Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? ⁶²	Shallis RM...Zeidan AM	32460977	2020
41	A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review. ⁶²	Ibrahim FA...Yassin MA	32398637	2020
42	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. ⁶²	Fang H...Reichard KK	31977035	2020
43	Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. ⁶²	Ye MT...You MJ	31750750	2020
44	Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. ⁶²	Sadigh S...Hobbs G	31904665	2020
45	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. ⁶²	Mangaonkar AA...Patnaik MM	31511613	2020
46	CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. ⁶²	Dal Molin A...Bortoluzzi S	33490078	2020
47	Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. ⁶²	Marcu A...Colita A	32328464	2020
48	Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53. ⁶²	Wang Q...Zhang R	33194542	2020
49	Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. ⁶²	Xie W...Tang G	31017498	2019
50	Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome. ⁶²	Turner SA...Mason EF	31230491	2019

Sources

Genes for Myelodysplastic/myeloproliferative Neoplasm

Genes related to Myelodysplastic/myeloproliferative Neoplasm (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	13.36	DISEASES inferred ¹⁴ ¹⁴
2	LUC7L2	LUC7 Like 2, Pre-MRNA Splicing Factor	Protein Coding	10.4	DISEASES inferred ¹⁴ ¹⁴
3	PTPN11	Protein Tyrosine Phosphatase Non-Receptor Type 11	Protein Coding	8.49	DISEASES inferred ¹⁴
4	SETBP1	SET Binding Protein 1	Protein Coding	8.21	DISEASES inferred ¹⁴
5	ASXL1	ASXL Transcriptional Regulator 1	Protein Coding	7.68	DISEASES inferred ¹⁴
6	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	7.59	DISEASES inferred ¹⁴
7	NF1	Neurofibromin 1	Protein Coding	7.58	DISEASES inferred ¹⁴
8	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	7.46	DISEASES inferred ¹⁴
9	ETNK1	Ethanolamine Kinase 1	Protein Coding	7.39	DISEASES inferred ¹⁴
10	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	7.37	DISEASES inferred ¹⁴
11	JAK2	Janus Kinase 2	Protein Coding	7.32	DISEASES inferred ¹⁴
12	SRSF2	Serine And Arginine Rich Splicing Factor 2	Protein Coding	7.19	DISEASES inferred ¹⁴
13	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	7.16	DISEASES inferred ¹⁴
14	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	7.1	DISEASES inferred ¹⁴
15	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	6.91	DISEASES inferred ¹⁴
16	ETV6	ETS Variant Transcription Factor 6	Protein Coding	6.72	DISEASES inferred ¹⁴
17	U2AF1L4	U2 Small Nuclear RNA Auxiliary Factor 1 Like 4	Protein Coding	6.67	DISEASES inferred ¹⁴
18	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	6.57	DISEASES inferred ¹⁴
19	CSF2	Colony Stimulating Factor 2	Protein Coding	6.51	DISEASES inferred ¹⁴
20	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.41	DISEASES inferred ¹⁴
21	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	6.37	DISEASES inferred ¹⁴
22	ZRSR2	Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2	Protein Coding	6.33	DISEASES inferred ¹⁴
23	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	6.31	DISEASES inferred ¹⁴
24	NPM1	Nucleophosmin 1	Protein Coding	6.27	DISEASES inferred ¹⁴
25	CD34	CD34 Molecule	Protein Coding	6.26	DISEASES inferred ¹⁴
26	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	6.24	DISEASES inferred ¹⁴
27	SOS1	SOS Ras/Rac Guanine Nucleotide Exchange Factor 1	Protein Coding	6.22	DISEASES inferred ¹⁴
28	GATA2	GATA Binding Protein 2	Protein Coding	6.2	DISEASES inferred ¹⁴
29	CALR	Calreticulin	Protein Coding	6.19	DISEASES inferred ¹⁴

Sources

Variations for Myelodysplastic/myeloproliferative Neoplasm

Sources

Expression for Myelodysplastic/myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myelodysplastic/myeloproliferative Neoplasm.

Sources

Pathways for Myelodysplastic/myeloproliferative Neoplasm

Pathways directly related to Myelodysplastic/myeloproliferative Neoplasm:

#	Pathway	Source
1	Signaling by cytosolic FGFR1 fusion mutants	Reactome ⁶⁶

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 58)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.78	ABL1 ETV6 FLT3 HRAS JAK2 KIT
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.77	PDGFRB NRAS NF1 KIT JAK2 HRAS
3	Signal Transduction ⁶⁶	13.75	PTPN11 PDGFRB NRAS NF1 KIT JAK2
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.62	PDGFRB NRAS KIT JAK2 HRAS FLT3
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.38	CSF2 CSF3R FLT3 HRAS JAK2 KIT
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.31	PTPN11 NRAS JAK2 HRAS FLT3 CSF3R
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.19	PTPN11 PDGFRB NRAS KIT JAK2 HRAS
8	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.08	PTPN11 PDGFRB NRAS NF1 KIT JAK2
9	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.83	PDGFRB NRAS KIT JAK2 HRAS
10	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.81	PDGFRB NRAS KIT JAK2 HRAS FLT3
11	CNTF Signaling ⁶⁴ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ FLT3 Signaling ⁶⁴ G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Host-pathogen interaction of human coronaviruses - MAPK signaling ⁷⁴ IL-3 Pathway ⁶⁴ Immune response Oncostatin M signaling via MAPK in human cells ²² Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells ⁷⁴ MAPK cascade ⁷⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.66	PTPN11 NRAS JAK2 HRAS FLT3
12	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.63	PTPN11 PDGFRB NRAS KIT JAK2 HRAS
13	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.57	PTPN11 PDGFRB NRAS JAK2 HRAS
14	Malignant pleural mesothelioma ⁷⁴	12.57	PDGFRB KIT HRAS FLT3 CSF2 ASXL1
15	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.4	PTPN11 NRAS JAK2 HRAS
16	MAPK signaling pathway ⁷⁴	12.4	PDGFRB NRAS NF1 HRAS
17	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.4	FLT3 HRAS NRAS PTPN11
18	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.39	HRAS JAK2 NF1 PTPN11
19	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.39	PTPN11 PDGFRB NRAS KIT HRAS
20	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.38	PDGFRB NRAS KIT HRAS FLT3
21	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.26	PTPN11 PDGFRB JAK2 ABL1
22	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.26	PTPN11 PDGFRB NRAS KIT JAK2 HRAS
23	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.2	PDGFRB NRAS HRAS CSF3R
24	Oncogenic MAPK signaling ⁶⁶ Show member pathways Signaling by BRAF and RAF1 fusions ⁶⁶	12.13	NRAS NF1 JAK2 HRAS
25	Tyrosine Kinases / Adaptors ³	12	PDGFRB KIT JAK2 FLT3 ABL1
26	FLT3 signaling in disease ⁶⁶ Show member pathways FLT3 Signaling ⁶⁶ FLT3 signaling by CBL mutants ⁶⁶ FLT3 signaling through SRC family kinases ⁶⁶ Negative regulation of FLT3 ⁶⁶ Signaling by FLT3 fusion proteins ⁶⁶ Signaling by FLT3 ITD and TKD mutants ⁶⁶ STAT5 Activation ⁶⁶ STAT5 activation downstream of FLT3 ITD mutants ⁶⁶	11.97	PTPN11 NRAS HRAS FLT3 ETV6
27	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.96	PTPN11 KIT JAK2 HRAS
28	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.95	KIT FLT3 CSF3R CSF2
29	MAP Kinase Signaling ³	11.93	HRAS NF1 NRAS PTPN11
30	Gastrin signaling pathway ⁷⁴	11.92	PTPN11 KIT JAK2 HRAS
31	DNA damage response (only ATM dependent) ⁷⁴	11.91	NRAS HRAS ABL1
32	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.89	PTPN11 NRAS HRAS
33	Immune response IL-2 activation and signaling pathway ²² Show member pathways IL-2 signaling pathway ⁷⁴ Immune response IL-3 activation and signaling pathway ²²	11.86	PTPN11 JAK2 HRAS
34	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.85	PDGFRB KIT FLT3
35	Signaling by Erythropoietin ⁶⁶ Show member pathways EPO signaling pathway ⁶¹ Erythropoietin activates Phosphoinositide-3-kinase (PI3K) ⁶⁶ Erythropoietin activates Phospholipase C gamma (PLCG) ⁶⁶ Erythropoietin activates RAS ⁶⁶ Erythropoietin activates STAT5 ⁶⁶	11.82	PTPN11 NRAS JAK2 HRAS
36	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.75	KIT FLT3 CSF2
37	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.75	PTPN11 PDGFRB NRAS HRAS
38	IL3-mediated signaling events ⁶¹ Show member pathways GMCSF-mediated signaling events ⁶¹ IL5-mediated signaling events ⁶¹	11.72	PTPN11 JAK2 CSF2
39	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.72	HRAS JAK2 KIT NRAS PTPN11
40	Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Aripiprazole Pathway, Pharmacokinetics ⁶⁰ Bosutinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ In progress: Docetaxel Pathway, Pharmacokinetics ⁶⁰ Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Taxane Pathway, Pharmacokinetics ⁶⁰	11.67	PDGFRB KIT ABL1
41	BDNF-TrkB signaling ⁷⁴ Show member pathways Synaptic signaling pathways associated with autism spectrum disorder ⁷⁴	11.65	NRAS NF1 HRAS
42	Signaling by CSF3 (G-CSF) ⁶⁶ Show member pathways Inactivation of CSF3 (G-CSF) signaling ⁶⁶	11.6	PTPN11 JAK2 CSF3R
43	SHP2 signaling ⁶¹	11.58	PTPN11 PDGFRB JAK2
44	Signaling by PDGFR in disease ⁶⁶ Show member pathways Signaling by cytosolic PDGFRA and PDGFRB fusion proteins ⁶⁶ Signaling by membrane-tethered fusions of PDGFRA or PDGFRB ⁶⁶ Signaling by PDGFRA extracellular domain mutants ⁶⁶ Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants ⁶⁶	11.56	NRAS HRAS ETV6
45	Signaling events mediated by PTP1B ⁶¹	11.5	PDGFRB JAK2 ABL1
46	Ras signaling ⁷⁴	11.49	PTPN11 PDGFRB NRAS NF1 KIT HRAS
47	Interleukin-11 signaling pathway ⁷⁴	11.48	PTPN11 JAK2 HRAS
48	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.47	PDGFRB NRAS HRAS
49	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.39	PDGFRB NRAS HRAS
50	Syndecan-2-mediated signaling events ⁶¹	11.33	NF1 HRAS CSF2

Sources

GO Terms for Myelodysplastic/myeloproliferative Neoplasm

Cellular components related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	U2AF complex	GO:0089701	9.26	U2AF1L4 U2AF1
2	granulocyte macrophage colony-stimulating factor receptor complex	GO:0030526	8.92	JAK2 CSF2

Biological processes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.3	PDGFRB KIT JAK2 HRAS FLT3 CSF2
2	positive regulation of cell migration	GO:0030335	10.27	CSF2 HRAS JAK2 KIT PDGFRB
3	protein autophosphorylation	GO:0046777	10.18	ABL1 FLT3 JAK2 KIT PDGFRB
4	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.1	PDGFRB KIT JAK2 FLT3
5	positive regulation of fibroblast proliferation	GO:0048146	10.09	PDGFRB HRAS ABL1
6	positive regulation of MAPK cascade	GO:0043410	10.09	PDGFRB KIT JAK2 HRAS FLT3
7	phosphorylation	GO:0016310	10.08	PDGFRB KIT JAK2 FLT3 ETNK1 ABL1
8	cytokine-mediated signaling pathway	GO:0019221	10.07	CSF3R FLT3 JAK2 KIT PTPN11
9	positive regulation of MAP kinase activity	GO:0043406	10.06	PDGFRB KIT HRAS FLT3
10	peptidyl-tyrosine phosphorylation	GO:0018108	10.02	PDGFRB KIT JAK2 FLT3 ABL1
11	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.01	KIT JAK2 FLT3 CSF2
12	positive regulation of phosphatidylinositol 3-kinase activity	GO:0043552	10	FLT3 KIT PDGFRB
13	myeloid cell differentiation	GO:0030099	9.91	TET2 JAK2 CSF2
14	myeloid progenitor cell differentiation	GO:0002318	9.9	KIT FLT3
15	positive regulation of leukocyte proliferation	GO:0070665	9.89	JAK2 CSF2
16	platelet-derived growth factor receptor-beta signaling pathway	GO:0035791	9.88	PDGFRB ABL1
17	mast cell proliferation	GO:0070662	9.86	NF1 KIT
18	granulocyte-macrophage colony-stimulating factor signaling pathway	GO:0038157	9.85	JAK2 CSF2
19	regulation of MAPK cascade	GO:0043408	9.75	PTPN11 NF1 KIT
20	positive regulation of phospholipase C activity	GO:0010863	9.73	PDGFRB KIT HRAS
21	platelet-derived growth factor receptor signaling pathway	GO:0048008	9.5	PTPN11 PDGFRB JAK2 ABL1
22	positive regulation of protein modification process	GO:0031401	9.33	PDGFRB KIT FLT3
23	regulation of cell population proliferation	GO:0042127	9.23	NF1 KIT HRAS FLT3 CSF2 ABL1

Molecular functions related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.85	PDGFRB KIT FLT3
2	nucleotide binding	GO:0000166	9.76	ABL1 ETNK1 FLT3 HRAS JAK2 KIT
3	SH2 domain binding	GO:0042169	9.73	KIT JAK2 ABL1
4	pre-mRNA 3'-splice site binding	GO:0030628	9.62	U2AF1L4 U2AF1
5	kinase activity	GO:0016301	9.5	PDGFRB KIT JAK2 FLT3 ETNK1 ABL1
6	protein tyrosine kinase activity	GO:0004713	9.32	PDGFRB KIT JAK2 FLT3 ABL1